Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor RNA-transfected dendritic cells
- Development stage
- Phase 2
- Lead developer
- National Center for Research Resources
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
This is an experimental autologous dendritic cell vaccine transfected with amplified tumor mRNA, developed for the treatment of metastatic prostate cancer. The therapy involves isolating a patient's own monocyte-derived dendritic cells and transfecting them with total tumor RNA amplified from a biopsy of the patient's tumor. This approach is designed to present a broad spectrum of tumor-associated antigens to the immune system, thereby stimulating a polyclonal cytotoxic T lymphocyte (CTL) response and minimizing the risk of tumor escape. The vaccine was investigated in a Phase I safety and feasibility study (NCT00006430) supported by the National Center for Research Resources (NCRR).
- Other names
- autologous dendritic cells transfected with amplified tumor RNAtumor RNA-transfected DC vaccine
02
Targets
Tumor-associated antigens derived from autologous tumor RNA
Beyond the preview
Go deeper on autologous tumor RNA-transfected dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor RNA-transfected dendritic cells.